The burden of RSV-associated illness in children aged < 5 years, South Africa, 2011 to 2016
Abstract Background Vaccines and monoclonal antibodies to protect the very young infant against the respiratory syncytial virus (RSV)-associated illness are effective for limited time periods. We aimed to estimate age-specific burden to guide implementation strategies and cost-effectiveness analyses...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2023-04-01
|
| Seri Bilgileri: | BMC Medicine |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s12916-023-02853-3 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|
